Pyrrolidinyl Sulfone RORγ Modulators for Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents fail to adequately address the inflammatory and autoimmune diseases associated with dysregulated IL-17 production, highlighting a need for compounds that can modulate RORγt activity to provide therapeutic benefits.
Innovation Solution
Development of compounds of formula (I) and their pharmaceutical compositions that can antagonize RORγ in cells and treat diseases by administering a therapeutically effective amount to subjects suffering from inflammatory, autoimmune, allergic, metabolic, or cancer-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic agents are used to treat inflammatory and autoimmune diseases, then treatment is provided, but the diseases are not adequately addressed due to failure to effectively modulate RORγt activity
Solution Approach 1:
The patent modifies the chemical structure of RORγt modulators by changing parameters such as introducing a pyrrolidinyl sulfone group at the R2 position of the core structure, substituting R1 and R3 positions with specific heterocyclic groups, and adjusting substituent patterns. These structural parameter changes result in compounds with enhanced affinity and selectivity for RORγt, thereby improving therapeutic effectiveness in controlling IL-17 production.
Solution Approach 2:
The patent creates composite molecular structures by combining a core scaffold with specific heterocyclic substituents (pyrrolidinyl, piperidinyl, morpholinyl groups) and functional moieties (sulfone, carbonyl, amine groups). This composite approach allows the molecule to simultaneously interact with multiple binding sites on the RORγt receptor, enhancing both affinity and functional modulation to address dysregulated IL-17 production.
2Reliability
If compounds of formula (I) are developed to antagonize RORγ, then therapeutic benefits are provided, but the complexity of compound synthesis and characterization increases
Solution Approach 1:
The patent divides the complex molecule into distinct functional segments: a core scaffold structure, heterocyclic substituent groups (pyrrolidinyl, piperidinyl, morpholinyl), and functional moieties (sulfone, carbonyl, amine). This segmentation allows for modular synthesis where each component can be prepared and assembled separately, reducing the overall complexity of compound production while maintaining the required therapeutic properties.
Solution Approach 2:
The patent designs a universal core scaffold that can accommodate multiple types of heterocyclic substituents at defined positions (R1, R2, R3). This multi-functional core structure allows a single synthesis pathway to generate multiple variants by simply changing the substituent groups, thereby reducing the number of separate synthesis procedures needed while producing a diverse library of therapeutically active compounds.
3Object-generated harmful factors
If RORγt activity is modulated to treat diseases, then IL-17 production is inhibited, but off-target effects and safety issues may arise
Solution Approach 1:
The patent introduces specific heterocyclic groups (pyrrolidinyl, piperidinyl, morpholinyl) at specific positions (R1, R2, R3) of the core structure to create local chemical environments that enhance selectivity for the RORγt receptor. The pyrrolidinyl sulfone group at R2, for example, provides specific hydrogen bonding and hydrophobic interactions that are unique to RORγt binding sites, thereby improving local binding quality and reducing off-target effects.
Solution Approach 2:
The patent employs structure-activity relationship (SAR) analysis to identify and replicate successful structural features from lead compounds. By copying and refining the heterocyclic substituent patterns that demonstrate high affinity and selectivity for RORγt, the patent creates a series of compounds that maintain therapeutic efficacy while minimizing off-target binding to other nuclear receptors or signaling pathways.
Data Source
AI summary
Described are RORγ modulators of the formula (I),or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.